Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.
about
Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathySuppression of laser-induced choroidal neovascularization by oral administration of SA3443 in mice.Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy.Neutrophils compromise retinal pigment epithelial barrier integrityTriamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat modelShort-term effects of intravitreal triamcinolone acetonide injection on ocular blood flow evaluated with color Doppler ultrasonography.IVTA as adjunctive treatment to PRP and MPC for PDR and macular edema: a meta-analysis.Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection.Macular atrophy after combined intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization.Effects of intravitreal triamcinolone acetonide injection with and without preservative.Downregulation of VEGF mRNA expression by triamcinolone acetonide acetate-loaded chitosan derivative nanoparticles in human retinal pigment epithelial cells.Triamcinolone acetonide prevents enhancement of hypoxia-induced neuronal and inducible nitric oxide synthases in the retinas of rats with oxygen-induced retinopathy.Posterior subtenon triamcinolone acetonide in gas-filled eyes as an adjunctive treatment for complicated proliferative diabetic retinopathy.Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases.Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone.Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma.Retinal Angiogenesis Effects of TGF-β1 and Paracrine Factors Secreted From Human Placental Stem Cells in Response to a Pathological Environment.Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month rRecent drug therapies for corneal neovascularization.OCT parameters in patients with diabetic maculopathy.Visual acuity outcome in patients with diabetic maculopathyBilateral Severe Sterile Inflammation with Hypopyon after Simultaneous Intravitreal Triamcinolone Acetonide and Aflibercept Injection in a Patient with Bilateral Marked Rubeosis Associated with Ocular Ischemic Syndrome.Acute retinal necrosis after intraocular triamcinolone acetonide injection.Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.The problem of pressure elevation associated with intravitreal triamcinolone.Severe corneal changes following intravitreal injection of bevacizumab.Treatment with triamcinolone acetonide prevents decreased retinal levels of decorin in a rat model of oxygen-induced retinopathy.Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection.Effect of intravitreal triamcinolone acetonide in the treatment of experimental Staphylococcus epidermidis endophthalmitis.Intravitreal triamcinolone acetonide as an adjunct in the treatment of severe ocular toxoplasmosis.Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.
P2860
Q24672544-67AFD25D-6890-450B-8B85-960217DC49D5Q33225324-BF53B589-A888-4A78-8368-B1DBAA53931BQ33431322-A1D0ACB3-1E37-49D2-921C-CDF2AD58E519Q33700898-B5317882-451E-4E5E-A416-6563DEF4AE74Q34272294-091AA0D2-C359-4BD3-ACBE-8C08224BF468Q34390554-F26DA598-9A63-4567-AD9F-08EA757C1206Q34413735-3B04A4EB-82C4-4B4E-9A3F-9246848AE9DDQ35089799-0E2D727A-512B-4863-B9E9-51D5AFB171BFQ35688128-6FAFD298-B841-47CC-84C4-07EB63CC8C49Q35691908-3A1A160C-8901-4166-8230-006AE873A111Q35924041-0A34B748-A63B-47FD-BC09-898DFF901088Q35953960-49F50DED-203F-4F38-A5A9-59F5040AE561Q36191344-8DEB5F9A-31BF-4285-A968-6CB44EDA91CBQ36424494-4BB36458-3868-4905-91B8-57C455AC666BQ36549150-FBA105E7-5CA0-4E3E-B466-3734F6651AF7Q36737173-08218FAD-509C-46AE-AC92-68627B295F53Q37233253-67622761-EBD6-4762-A40B-1832E85E9283Q37879167-6560B682-B452-438A-9923-91FE00B805EFQ38149120-78FA39CE-55FD-4A55-8451-D6F4BA740CC0Q38425315-7F8A154D-69DB-423F-B407-B3974EA4BEB1Q38731129-7CFE919C-723D-4B61-98B5-48F856DB04F3Q39295602-D326FED4-4B30-4524-AD57-18207FDC36D0Q39444329-A881809A-9178-434D-A435-88B279E69348Q39444634-6F251E5A-2841-43B2-80F4-CA1BCD376E83Q41819857-A2446B6B-CBFE-4F26-BA3D-F6D2C92BED89Q42075612-43DD3EBE-FDEF-4BFE-A288-E23D8285A3C1Q42634677-7BDF52B2-68FD-4D95-AC97-EA6171B7D7B8Q42841761-521543E5-A6BA-42BF-901C-6276A4A5B35DQ42956425-66A833D2-7331-4F15-A48D-0B01D5060111Q42992147-2FACF4C6-0F58-45E1-98B1-D96414920FC4Q45935983-04C63743-2B85-4E40-9067-0E43C0500DC0Q46121000-E4A1FE12-BB08-47E3-A02A-1DEBBB3D1594Q46732140-F14F1F9E-7284-4D14-B3F9-EFC64AF6C193Q46893247-25EA4394-83F6-4BE5-BB70-18C62278738B
P2860
Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Intravitreal triamcinolone ace ...... ive, and neovascular diseases.
@ast
Intravitreal triamcinolone ace ...... ive, and neovascular diseases.
@en
type
label
Intravitreal triamcinolone ace ...... ive, and neovascular diseases.
@ast
Intravitreal triamcinolone ace ...... ive, and neovascular diseases.
@en
prefLabel
Intravitreal triamcinolone ace ...... ive, and neovascular diseases.
@ast
Intravitreal triamcinolone ace ...... ive, and neovascular diseases.
@en
P1476
Intravitreal triamcinolone ace ...... ive, and neovascular diseases.
@en
P2093
Ingrid Kreissig
Robert Degenring
P304
P356
10.1016/J.PRETEYERES.2005.01.004
P50
P577
2005-03-29T00:00:00Z